A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

Scientists have made a discovery which could lead to the first change in standard liver cancer treatment in 20 years. Two ...

China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.

Immunotherapy, a form of treatment that uses the body’s immune system to find and fight cancer cells, can delay the ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

Martin Dreyling, MD, discusses how the safety and efficacy results from the TRIANGLE study in mantle cell lymphoma differ from prior expectations.

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — warrants further investigation, according to researchers.